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Epidemically, infectious diseases had always remained one of the leading 
causes of mortality and therefore are identified as a public health issue all 
around the world. It has been reported that one of the major cause of bacterial 
pathogens increasing at an alarming rate are due to over-prescription, general, 
aimless and pervasive use of antibiotics for both medical and non-medical 
means and generating  multi drug resistance due to these pathogenic bacteria. 
The situation has been worsened due to serious decline in the level and 
quality of industrial research aimed for developing novel antimicrobial drugs.   
We interrogating synthetic human defensins antimicrobial peptides analogs 
by chemical synthesis will provide intuition of its architecture, function, and 
antimicrobial properties. In this project, six peptide sequences were selected 
from α- and β human defensins, synthesized by solid phase peptide synthesis 
(SPPS) and purified by high pressure liquid chromatography (HPLC). Mass 
spectrometry was used to analyze the mass of synthetic peptides and their 
purity. Minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) was used to measure antimicrobial spectrum against 
Streptococcus epidermidis and Pseudomonas aeruginosa. MIC were also 
used for evaluation of their turgidity in presence of microorganisms. MBC 




microorganisms. The main outcome of this work was producing antimicrobial 
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Chapter 1: Literature Review 
 
1.1. Protein and Peptides 
Proteins are captivating bio-molecular devices present in nature. They can 
receive or send information and have certain catastrophic functions such as 
divergence, recruitment and mixing/matching of domains. Divergence is 
change in sequence and structure, lead to change in specificity and nature of 
the reaction catalyst. One protein adapted without any structural change for 
second function is called recruitment. During the ‘mixing and matching of 
domains, mass scale structural changes occur in the surrounding environment 
[1]. Dr Francis Crick proposed the idea of protein formation in his statement 
called Central Dogma of molecular biology in 1958 [2]. This statement 
brought a revolution in the proteins and proteomics world.  
Proteins are made up of polymer chains of amino acids e.g. polysaccharides. 
They are the main essential energetic agents in molecular biochemistry; in the 
absence of them no metabolic processes can happen [3]. The 3D structure and 
function of proteins depend strongly on the sequence of the different amino 
acids  (Figure-1) [4].  





Figure 1: Illustration representing the diverse function of proteins. 
Amino acids have different physicochemical properties and structures. For 
example some are polarized or non-polarized, charged or neutral, 
hydrophobic or hydrophilic, basic or acidic [5]. These differences are 
characterized by a central carbon atom to which a hydrogen atom, a carboxyl 
group (—COO-), an amino group (—NH3
+) and a side chain (R) are attached. 
These amino acids are named as the building bricks of proteins. The names of 
amino acids are not systematic; they are abbreviated by their first three letters 




except of Asparagine (Asn), Glutamine (Gln), Isoleucine (Ile) and 
Tryptophan (Trp) (Table 1) [6].  
Table 1: Molecular weight, abbreviation, charge, and nature of amino acids 




Charges  Nature One 
Letter 
Alanine 311.33 g/mole Ala Uncharged Hydrophobic A 
Valine 339.39 g/mole Val Neutral Hydrophobic V 
Arginine 648.77 g/mole Arg Positive + Hydrophilic R 
glutamic acid 526.54 g/mole Glu Negative - Hydrophilic E 
Leucine 353.41 g/mole Leu Neutral Hydrophobic L 
Proline 337.37 g/mole Pro Uncharged Hydrophobic P 
Tyrosine 403.43 g/mole Tyr Neutral Hydrophobic Y 
Threonine 397.46 g/mole Thr Uncharged Hydrophilic T 
Serine 327.33 g/mole Ser Uncharged Hydrophilic S 
Phenylalanine 387.43 g/mole Phe Neutral Hydrophobic F 
Lysine 468.54 g/mole Lys Positive + Hydrophilic K 
Isoleucine 353.41 g/mole IIe Neutral Hydrophobic I 
Histidine 619.71 g/mole His Positive + Hydrophilic H 
Glycine 297.31 g/mole Gly Uncharged Hydrophilic G 
Glutamine 368.38 g/mole Gln Uncharged Hydrophilic Q 
Cysteine 585.71 g/mole Cys Uncharged Hydrophilic C 
Aspartic Acid 411.45g/mole Asp Negative - Hydrophilic D 
Asparagine  580.63g/mole Asn Uncharged Hydrophilic N 
Methionine 371.45 g/mole Met Neutral Hydrophobic M 
Tryptophan 426.46 g/mole Trp Neutral Hydrophobic W 
 
Biochemically, the presence of amino acids in the human body is divided as 
e.g. Essential, Non-essential and Conditional amino acids. The essential 
amino acids (Leucine, Isoleucine, Lysine, Threonine, Methionine, 
Phenylalanine, Valine and Tryptophan) are not synthesized in the human 
body but are supplied by food. Although there are many classifications 
proposed for amino acids, Table 2 below presents a widely accepted 
classification. 




Table 2:  Classification of amino acids according to nature 
CLASS NAME OF AMINO ACIDS 
Aliphatic Leucine, Isoleucine, Glycine, Valine, and Alanine 
Neutral Asparagine, Serine, Threonine, and Glutamine 
Acidic Glutamic acid and Aspartic acid 
Basic Arginine and Lysine 
Aromatic Phenylalanine, Tryptophan, and Tyrosine 
 
In Figure 2, it is clear that all amino acids have different structural 
architecture due to differences in side chains. Some side chains are charged 
for example lysine/arginine are positively charged and glutamic acid/aspartic 
acid are negatively charged. These charged atoms are located at or near the 
end of flexible and long side chains. A few amino acids have polar side 
chains e.g., threonine, tyrosine and serine contain hydroxyl groups whereas 
glutamine and asparagine contain amide groups and the remaining side chains 
are electrically neutral and because of thermodynamically undesirable 
interactions of hydrocarbons with water, they are called ‘hydrophobic’ 
residues [7]. During polymerized, 50 or less amino acids form short chains 
that are joined by peptide bonds to formed then called peptides. When the 
peptide chains stretch or extend over 50 amino acids then polypeptides are 
formed. Similarly, proteins are formed by multiple polypeptides joined 
together. Small adjustments in the amino acids sequence can switch the 
nature of proteins [7].      





Figure 2: Structural architecture of natural amino acids [1]. 
 
Primary, secondary and tertiary levels of protein structure were described by 
Dr. Kaj. Ulrik Linderstrøm-Lang (Danish protein chemist) and the quaternary 
level was proposed by Dr. John. D. Bernal in 1934. The primary structure is a 
basic structure, which is determined by the amino acids sequence plus the 
intra/interchain cross-links. Some rotational movements, lengthening of the 
amino acids chain and hydrogen bonding (H-bonds) will shape the secondary 
structure. These polypeptides are flexible and can exhibit α- Helix and β- 
sheets structure, representing the secondary structure. The α-helix is formed 
by a single sequential set of amino acids sequence or creation of hydrogen 
bonding within the same chain e.g. myoglobin. In β- sheets, the main chains 




interact by lateral hydrogen bonding. The establishment of new proteins by 
combining or interaction of helices and sheets will lead to unusual 3-
dimensional spatial arrangements of chains that form tertiary structures or 
folding pattern. Quaternary structure form when the subunits or polypeptides 
of the same or different subunits merge together by secondary forces e.g., 
Hydrogen bonds, disulfide bonds, van der Waals forces and electrostatic 
forces. The three different structures of proteins are presented in Figure 3 
below [8].  
 
Figure 3: Illustration of the three different structures of proteins [8]. 
After the completion of protein structure, they are genetically coded for 
specific functions in the body e.g. regulation, defence, membrane 
transportation etc. Any interference in the production of proteins or 




prevention of binding at target active sites will cause loss of function and 
diseases such as Alzheimer’s and spongiform encephalopathy [9].  
1.2. Antimicrobial Peptides 
 
In nature, antimicrobial peptides (AMPs) are evolutionary weapons of 
multicellular organisms [10]. They are widely distributed in plant and animal 
kingdoms (vertebrates and invertebrates) as a weapon for offenses and 
defences. Pioneering studies discovering these peptides led to various host 
defence peptides, e.g., Defensins, cathelicidins, cecropins, histatins and 
magainins [11].      
A variety of AMPs have been discovered and isolated from different species 
including plants, animals, microorganisms, fungi and insects in the past 10 
years and these are identified for therapeutic functions [12]. Antimicrobial 
peptides are fascinating novel antibiotic molecules especially these days 
where antibiotic resistance is becoming a very serious problem [13].  
Advantages of peptides include  accessibility, practicality and simplicity [14]. 
AMPs are mostly located in the epithelial and non-epithelial surfaces in 
humans where they aid to maintain natural barriers and protect against 
microbial intervention. The AMPs activity begins when they come in contact 
with the target organism electrostatically. AMPs pass through the cell 
membrane by binding it and causing the alteration in structure following 
which they enter the cell and interact with the targets. They initiate the 




activity of autolytic enzymes and cease the cell wall biosynthesis, synthesis of 
DNA, RNA and protein. They possess immunomodulation functions; cause 
clearance of infection, promote wound healing, and modulate the responses 
of dendritic cells and cells of the adaptive immune response [15]. The 
classification of antimicrobial peptides is divided in groups-I, II, III and IV 
according to their composition and their three-dimensional structure. 
a) Group I: 
They are the most extensively studied AMPs containing α- helical peptides 
without cysteines [16]. They adopt disturbed or disordered structures in 
water and fold into α-helical conformation upon interaction with 
hydrophobic solvents or lipid surfaces e.g., magainins [17]. Magainins 
secreted from African clawed frog (Xenopus laevis) contains 23 amino 
acids [18]. These α- helical peptides are absorbed or inserted into the 
membrane as a cluster of helical bundles and often are found as 
amphipathic with selective toxicity for microbes [19].  
b) Group II: 
In comparison to group I, these peptides contain cysteine residues linked 
by disulfide bridges e.g., human defensins [20], protegrin [21], 
lectoferricin [22], tachyplesins [23], gramicidin S [24], polymyxin B [25], 
and tyrocidines [26]. These peptides form β- sheets which are stabilized by 
interaction with lipid surfaces [27].  
 




c) Group III: 
These AMPs have unusually high proportion of one specific or two amino 
acids sequence for example histatin. Histatin is highly rich in histamine 
(His) and is produced in saliva, it acts as potent antifungal and 
antibacterial having a significant wound healing activity [28]. Other 
examples of this group are cathelicidins [29], tritrpticin 
(VRRFPWWWPFLRR) [30] and indolicidin (ILPWKWPWWPWRR-
amide) [31] . In this group of peptide translocate them across the yeast 
membrane and targets to the mitochondria of microorganisms [32]. 
 
d) Group IV: 
These peptides contain a looped structure; they are short in size and can be 
easily synthesized with proteolytic stability upon binding to lipid 
membranes. This group of peptides contains Lantibiotics (Nisin) and have 
the capacity to fight against present and emerging infectious diseases [33].  
In the literature, another classification considers the presence of four 
large families of peptides; α, β, αβ, and non- αβ peptides [34]. Peptides 
belonging to α- family exhibit α-helical structure e.g., histatins, 
dermicidin, granulysin and human cathelicidins LL-37. These included in 
β-family have at least one pair of two β-strands in their structures e.g., 
human α-defensins and hepcidins. Peptides of the αβ-family contain both 
α- and β- structures compared to the non-αβ family that do not have any 




structure and are called as extended structured peptides [35]. On the basis 
of structural homology motifs, a different classification of families of 
antimicrobial peptides can be generated that reflects the relationship 
between family members. In humans, peptide antibiotics of three families 
have been identified: the defensins, cathelicidins, and histatins (Table 3). 
Table 3: Different types of antimicrobial peptides [36]. 
Peptide family Features 
Defensins They are greatly explicit and demonstrate bactericidal, antifungal and 
antiviral activity and are primarily found in cells and tissues of host 
defence. According to the position of the cysteins, defensins have 
been classified as α, β- and θ-defensins. 
Cathelicidins This family structurally diverse and located at carboxyl terminus. 
They are synthesized and stored in cells as two- domain proteins and 
on demand break in to cathelin protein or antimicrobial peptide. 
Histatins They are small, cationic, histidine-rich peptides. They are secreted by 
the oral salivary gland (parotid, submandibular and sublingual 
glands) and show a potent bactericidal and also fungicidal activity. 
Therefore play an important role in maintaining oral health by 
limiting infections in the oral cavity. 
 
1.2.1. Mechanism of Action 
There are extensive studies on antimicrobial peptides killing mechanism. 
Their amino acids compositions, cationic charges, amphipathicity and size 
allow them to attract and attach to bacterial lipid bilayer to form pores by 
‘carpet’, ‘barrel-stave’ or ‘toroidal-pore’ models (table -4) [37]. 
 




Table 4: This represents the different models of antimicrobial peptide 
mechanism of action against microbes. 
Model’s Description 
Carpet model Attracted or attached peptides aggregates and penetrate into the 
membrane bilayer. The hydrophilic peptide domain form the 
interior region of the pore and hydrophobic peptide domain align 
with the lipid core region. 
Barrel-Stave Model Peptides position themselves around the cell membrane for 
binding and this leads to conversion to a bilayer membrane with 
peptide aggregation. In this way, hydrophobic peptides attach to 
the lipid side, whereas hydrophilic peptides attach to the interior 
part of the cell membrane. 
Toroidal Model In this peptide helices put into the membrane and induce the lipid 
monolayers to bend constantly through the pore so that water 
core is lined by equally inserted peptides and the lipid head 
groups. 
 
Despite the fact that all these models are very beneficial for defining the 
mechanism of antimicrobial peptide activity, their pertinence to how peptide 
destroy or kill microorganisms needs still some justifications. In recent time, 
it has been contemplated that pore formation is not only for killing 
microorganisms. Many remarks come from different research groups for 
example; translocation of peptides from the cytoplasmic membrane to alter it, 
inhibition of synthesis (Nucleic acids, Protein and enzymatic activity) [37]. 
Different studies proved different mechanisms of action in antimicrobial 
peptides. Lehrer et.al observed that E. coli bacteria were killed in 15 minutes 
by DEFB118 forming membranous blebs and therefore decreasing the 
viability of the bacteria  [38].  Carol et al. published data on the cationic 
capability of antimicrobial peptides in comparison to customary bactericidal 
antibiotics. They observed that the minimum inhibitory concentration and the 




minimum bactericidal concentration of antimicrobial peptides are higher than 
conventional antibiotics and AMPs can destroy bacteria faster  compared to 
antibiotics (Figure 4) [39].  
 
 
Figure 4: Comparison of AMPs with conventional antibiotics in Mueller-
Hilton broth. Ceftazidime at 2 µg/mL, gentamicin at 0.5 µg/mL, CEMA at 4 
µg/mL and cationic peptide (CP-29) at 2 µg/mL, published data by Friedrich 
et al. [39]. 
 
The characteristics of AMPs are very important for killing microorganisms 
e.g. size, sequence, charge, structure, hydrophobicity and amphipathicity [40]. 
Magainins are 21- 23 peptide residues without cysteine and their activity 




against gram negative organisms is 10 times less than cecropins, that have a 
strongly basic N-terminal and are linked to neutral C-terminal by a pliable 
glycine-proline chain [41, 42]. The activity of amphipathic α-helical peptides 
is stronger than those peptides with less defined secondary structures [43]. 
AMPs are initially attracted toward the bacterial membrane by a mechanism 
of electrostatic bonding between anionic or cationic peptides. Then they 
attach to the membrane resulting in  thinning of the membrane, formation of 
pores, creation of holes, chaotic distribution of lipids between the bilayer and 
finally membrane disruption [10, 44, 45]. Figure 5 shows a proposed model 
for the mechanism of antimicrobial peptides against bacteria by Shai-
Matsuzaki-Huang (SMH). This model represents the mechanism through 
which antimicrobial peptides attack and destroy bacterial cells when they 
come in contact. Peptides bind to the outer surface of the bacterial cell 
membrane to alter in the architecture of the lipid bilayer. Lipids are displaced 
leading to the thinning of the bilayer and increase in the local surface tension 
causing the development of pores in the cell membrane thus, allowing 
penetration of peptides into the bacterial cell and causing their death [46].   
 





Figure 5: Model proposed by Shai-Matsuzaki-Huang (SMH) for the 
mechanism of action of antimicrobial peptides. (a) Wrapping of the outer 
leaflet with peptides. (b) Segregation of the peptide into the membrane 
and thinning of the outer leaflet. The surface area of the outer leaflet 
expands relative to the inner leaflet resulting in strain within the bilayer 
(jagged arrows). (c) Phase transition and `wormhole' formation. Transient 
pores form at this stage. (d) Transport of lipids and peptides into the inner 
leaflet. (e) Diffusion of peptides onto intracellular targets (in some cases). 
(f) Collapse of the membrane into fragments and physical disruption of the 
target cell's membrane. Lipids with yellow head groups are acidic, or 








1.2.2. Application in Medicine and Dentistry  
Antimicrobial peptides are competent to kill various infectious microbes and 
play a role as immunomodulatory therefore substantial efforts have been 
made to use them as potential therapeutic agents. The first antimicrobial 
peptide based therapeutic application was reported in 1944 by the Russian 
scientist Dr. Georgii F. Gause. He isolated Gramicidins (AMP) from Bacillus 
brevis. These peptides exhibit activity against a broad range of gram-positive 
bacteria both in vitro and in vivo. Their first clinical use was to successfully 
treat infectious wounds of guinea-pig skin [47]. After this phenomenal 
discovery, many other research groups started working on different 
microorganisms, plants, animals and elicited new antimicrobial peptide 
families [10, 42, 48].  Table-5 presents a peptides discovery list, sources and 
activities of synthetic antimicrobial peptides. 
Table 5: Discovery, sources and activity of synthetic antimicrobial peptides 
Name Year Sources Activity References 
Gramicidins 1944 Bacillus brevis Gram- positive [47] 
Lactoferrin 1960 Milk Gram – negative and 
positive 
[49] 
Bombinin 1962 Frog Kill bacteria and 
haemolytic activity 
[50-52] 







Cecropins 1981 Hylophora cecropia Bacillus subtilis and 
Enterobacter cloacae 
[54] 
Magainins -2 1987 Xenopus laevis Candida albicans [42] 




Protegrin 1991 Porcine leukocytes bacteria, fungi, and [55] 




some enveloped viruses 
Cathelicidins 1995 Mammalian myeloid 
cell 
Bacteria killing and 
promotion of wound 
healing 
[56, 57] 
Histatin 1987 Human parotid 
secretion 
Fungistatic effects [28, 58] 
 
Denture stomatitis is a commonly reported disease of immune-compromised 
old patients due to poly methyl methacrylate (PMMA) denture base material 
and the adhesion of Candida albicans and biofilm formation. Yoshinari et al. 
synthesised chemically histatins (Hst)-5; antimicrobial peptides secreted by 
the parotid gland. AMPs were loaded in poly methyl methacrylate (PMMA) 
surfaces leading to a decrease in the formation of Candida albicans biofilm 
and  less colonisation of  C. albicans [59]. Pusateri et al.  loaded histatins 
(Hst)-5, β-Defensins (HBD)-3 and Chlorohexidine in preconditioned acrylic 
denture base samples in 500 µl saliva and concluded that the action of 
histatins (Hst)-5 as antimicrobials was very effective [60].  Oral candidiasis is 
another disorder caused  by dry mouth syndrome, immunocompromised and 
denture wearing patients [61]. In order to treat the above infection, Xanthan 
(artificial saliva) with cationic antimicrobial peptides have been used 
effectively [62]. 
Currently, during clinical use of biomaterials such as in contact lenses, tooth 
filling materials, bone cements, implanted cardiac valves, urinary catheters, 
endotracheal tubes, coronary stents and hip/dental implants, infections have 
been developed and manufacturers are keen to develop multifunctional 




devices with improved bioactivity, antimicrobial and anti-infective behaviour 
[63-65].  These approaches are described in detail with the use of examples in 
Table 6. 
Table 6: Approaches used to make antimicrobial biomaterials for tackling 
microbial infections. 
 Approach References 
1 Modification of the biomaterial surface to confer anti-adhesive 
properties; 
- Coatings based on hydrophilic polymeric brushes 
- Based on poly (ethylene glycol) (PEG) and/or poly (ethylene 
oxide) (PEO) 
- Bio-surfactants 
- Polyamidoamine  based dendrimers 
[66-68] 
2 Doping the material with antimicrobial substances 
- Antibiotic loaded biomaterials 
- Loading with disinfectants and bactericidal substances (e.g. NO+, 
Ag+, Zn2+, Cu2+, 
Chlorohexidine, lysozyme, metal nanoparticles) 
- Immobilized antimicrobial peptides 
[69-71] 
3 Combining anti-adhesive and antimicrobial coatings 
- Multilayer film constructed by assembling layer-by-layer heparin 
and chitosan 
- Covalent conjugation of antimicrobial peptides immobilized onto 
a hydrophilic polymer 
[67, 72, 73] 
4 Materials able to oppose biofilm formation and, at the same time, 
to support tissue integration 
- Silver containing hydroxyapatite coatings 
- Poly(L-lysine)-grafted-poly(ethylene glycol) functionalized with 
adhesive peptides such as RGD 
- Bio-glasses doped with gold nanoparticles 
[74-76] 
 
A successful in-vitro drug release, cytotoxicity and antimicrobial study was 
reported by Mehdi et al. In this study, in-vitro bone growth (osteo-
conductive) was achieved by using calcium phosphate coatings on medical 
grade titanium surfaces loaded with antimicrobial peptides (HHC36: 




KRWWKWWRR and Tet213: KRWWKWWRRC). The surfaces were 
successfully tested against Staphylococcus aureus and Pseudomonas 
aeruginosa [77].  Wilmes and Sahl et al reported very recently in their review 
about human defensins, the fascinating role of host defense peptide (HDP) in 
anti-infective drugs [78]. The presence of disulfide bridges in defensins raised 
the value of resistance against proteolytic degradation [79]. Human 1-4 β-
defensins play a key role in wound healing by migration and proliferating 
epidermal keratinocytes to promote healing [80, 81]. Antimicrobial peptides 
are suitable candidates to combat microbial colonies and inhibit biofilm 
formations [82, 83].  
1.3. Design of Antimicrobial Peptides  
 
There is currently huge demand for the use of alternative antimicrobial 
approaches that can lead to a decrease in antimicrobial resistance [43]. 
Peptides can be derived from three sources (a) Natural or bioactive peptides 
(produced by plants, animals or humans), (b) Use of genetic or recombinant 
technology for isolating peptides and (c) Use of chemical libraries for 
discovering peptides [40]. There are few estates modulated by peptide design 
and modification like increasing activity against microbial cells, heighten 
susceptibility against proteolytic degradation and reduction in immunological 
reactions against human cells [40, 48].  Reported data on designing 
antimicrobials include peptide analogues or hybridization through amino acid 




deletion of inactive or combining active motifs together for increased 
antimicrobial activity. Other methods include the chemical synthesis of 
antimicrobial peptides mimicking natural antimicrobial peptides and 
screening peptide structural-activity relationship from combinatorial libraries 
for better understanding [84]. Usually, the amount and size of the peptide 
sequence determines the method of their production e.g., Chemical synthesis, 
soluble fusion expression method, recombinant DNA technology, cell-free 
expression system, plant or enzymatic method [85]. Especially, synthetic 
therapeutic peptides production has become possible for pharmaceutical 
companies or biotech laboratories with the introduction of solid-phase peptide 
synthesis (SPPS) by Merrifield and his work on three principle sequential 
synthesis, convergent synthesis and chemical ligations [86, 87]. Very recently 
R. Jiang and S.S.J. Leong et al. reported a new method “Intein based 
bioprocess” for synthesizing AMP as an alternative to solid-phase peptide 
synthesis (SPPS); this method is cheaper, eco-friendly to manufacture for 11-
mer synthetic antimicrobial peptides [88].  
1.4. Human Defensins  
Defensins are a large family of antimicrobial peptides with molecular weight 
of 4-5 kDa and more extensively studied as well. Defensins are short peptides 
(less than 50 amino acids) with positive net charge, cationic, and meaningful 
proportion of hydrophobic residues that permit to adopt amphipathic 




structures in membrane mimicking environments [89]. These peptides contain 
6-8 cysteine residues which form 3-4 disulfide bonds with arginine and 
aromatic residues. These cysteines are linked in 1-6, 2-4 and 3-5 positions.  
This family is subdivided into α-, β- and θ-defensins on the basis of molecular 
architecture and connectivity of disulfide-bonds. During the last decades, 
sequences of endogenous α- , β- and θ-defensins were identified [78]. Their 
sources and history are presented in Table-7. Both α & β- defensins were 
found in breast milk, marking the role of defensins in protecting infants from 
infections. 
Table 7: History and sources of defensins peptides. 
Name Discovery Source  Reference 
α- Defensins (1-4) 1980s Human neutrophil granules [90] 
α- Defensins (5-6) 1992-1993 Small intestinal Paneth cell [90] 
β-Defensins-1 1995 Purified from human plasma but 
also found in epithelial cells 
originate from the kidney, 
respiratory tract, pancreas, oral 
tissues (like parotid gland, buccal 
mucosa and tongue) and female 
reproductive tract. 
[91, 92] 
β- Defensins-2 1997 Extracted from lesional scales 
from psoriasis patient and is 
greatly found in skin, lung and 
trachea, also in gingival mucosa. 
[91, 92] 
β- Defensins-3 2000 It’s also extracted from lesional 
scales from patients suffering 
from psoriasis and also detected in 
the placenta, adult heart, skeletal 
muscles, thymus, oesophagus and 
trachea. 
[93] 
β- Defensins-4 2001 Present in high levels in the 
gastric antrum and testis. It’s also 
expressed in uterus, lungs and 
kidneys. 
[90, 91] 
β- Defensins-5 & 6 2002 Human epididymis [94] 




β- Defensins-25 to 27 2003 Their transcripts only exist in few 





1999 Isolated from leukocytes of 
Rhesus macaques.  
[95] 
 
1.4.1. Role of disulfide connectivity on the antimicrobial behaviour of human 
defensins 
Defensins are cysteine-rich and they have a β- sheet structure which is 
stabilized by three disulfide linkages. This chemical linkage is covalent and is 
derived by coupling of the two thiols groups. In α–defensins the disulfide 
bridges form between the first and the sixth cysteine residues (Cys1-Cys6), 
Cys2-Cys4, and Cys3-Cys5 , while in β–defensins, the  cysteine bridge form in 
Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6 residues [96]. It has been suggested that 
the antimicrobial activity of defensins depends upon this disulfide bridging. 
θ-Defensins are macrocyclic structures with disulfide linkages in between 
Cys1-Cys6, Cys2-Cys5, and Cys3-Cys4 residues [84]. Different disulfide 
linkages is believed to show variation in molecular structure and 
antimicrobial function but as Miguel et al. reported, the antimicrobial activity 
of human β- defensin-3 is independent of disulfide bridging. Only the 
chemotactic property is dependent on the disulfide bond formation [97]. In 
nature these disulfide bonds are taken care by the protease inhibitors and 
proteolysis [98]. In a molecular dynamic study (MDR) of human defensins 
(HNP-3 and HBD-1) by Nagaraj R. et al. it was reported, that non-native 




disulfide bonds are biologically active against bacteria in comparison with 
native disulfide bridged human defensins (HNP-3 and HBD-1) [99].  
1.4.2. Mechanism of antimicrobial action of human defensins   
The meticulous antimicrobial mechanism of defensins has not yet been 
clarified. It has been suggested that they can permeate the cell membrane 
through the formation of multimeric pores. The cationic nature and 
amphipathic characteristics enable binding to the cell membrane lipid bilayer 
leading to leakage of the internal content of the bacterial cells [78]. It has 
been  reported that all defensin precursors were established on the basis of 
similarities in architecture, sequences, mode of action, and inter-
physicochemical functionality [100] e.g., Myxobacteria (Anaeromyxobacter 
dehalogenans and Stigmatella aurantiaca) showed strong resemblance in 
sequences and construction to fungal defensins [101].  The human β- 
defensins have been widely studied and their role has been widely recognised 
as the main contributors of  innate immunity for direct action against gram-
positive and gram-negative bacteria [102], viruses [15], fungi and parasites 
[99].    
1.4.3. Types of Human Defensins 
1.4.3.1. α- Defensins 
In 1980s Lehrer et al. observed a biological molecule 29 to 35 amino acids 
long with cationic capability and expressed by human neutrophils [103]. 




Human α-defensins-1,-2,-3 and -4 are mainly synthesized by bone marrow 
neutrophil precursor cells (promyelocytes) and these mature peptide is stored 
in neutrophil granules [36] but human neutrophil peptide (HNP)-5 & -6 are 
emancipated as a propeptide which processed extracellularly [104]. Selsted et 
al. proposed a canonical sequence of α-defensins as x1-2CxCRx2-
3Cx3Ex3GxCx3Gx5CCx1-4, where x symbolises any amino acid residue [105].  
The structural homology of HNP 1-3 is highly similar to HNP-4 and the 
peptides have been studied as closed group and few studies revealed their 
antimicrobial and immunomodulatory functional distinctions [106].  Lehrer 
et.al demonstrated the direct action of HNP-1, HNP-2, and HNP-3 against 
herpes simplex virus (HSV) type 1 and 2, cytomegalovirus, vesicular 
stomatitis virus, and influenza virus. HNP-1 has a  more potent neutralizing 
effect against HSV-2 however, represented no activity against non-enveloped 










Figure 6: The amino acid sequence of α- human neutrophil peptides with 
cysteine bonding. 
 
1.4.3.2. β- Defensins 
In 1993, Selsted.et.al and co-workers isolated and purified bovine tracheal 
cells and observed 38-42 amino acid peptides, six-cysteine motifs creating 
three disulfide bonds [108].  Up-to-date six human β-defensins have been 
identified [89] and five gene-based searches (HBD-25 to HBD-29) reported 
by Peng Jia, Hong, et al and Yashwanth, et al [109, 110]. It is strongly 
evidenced by Hancock and Scott (2000), that β-defensins play a key role in 
the defence of mucosal and body  epithelial surfaces [111].  The canonical 
sequence of β-defensins is presented by Selsted.et.al as x2-10Cx5-6(G/A)xCX3-
4Cx9-13Cx4-7CCxn [108]. The highest endeavoured members of β –defensins 
are HBD-1, HBD-2 and HBD-3 because of highly effective killing capability 
for gram negative in comparison to α-defensins [112] and their expression 




identified in epithelial surface of external skin [102], oral mucosa [113], 
trachea, lungs [114] and uterus [115].   
 
Figure 7: Structures of - Defensins. 
 
14.3.3. θ- Defensins 
In recent years, a new family of lectin-like cyclic octapeptides are explicit 
from polymorph nuclear leukocytes (PMNs) of old world monkey (macaques 
and baboons) but not new world monkeys (gorillas and chimpanzees) [95]. 
They exit as RDT-1 to RDT-6 [116]. Selsted et al. suggested that the 
antibacterial activity of θ–defensins is greater compared to human α –
defensins and the RDT-1 ,-2 and -3 have similar antimicrobial activity [117]. 
θ-defensins may be conjugated from different head-to-tail splicing of non- 




peptides from the similar pro-θ-defensins precursor (Figure 8) [116].  Cole et 
al. identified a pseudogene from the human bone marrow that is encoded as 
antimicrobial peptide analogous to rhesus monkey mini-defensins (Circular 
peptides) with potent ability to restrain pro-viral DNA formations [118]. 
Previous study on synthetic retrocyclin-1 has shown effect on human immuno 
deficiency virus, type 1 (HIV-1) by inhibiting envelop mediated fusion at 
concentration of 4 to 6 µM [119]. 
 
Figure 8: Description of θ -defensin sequences. The blue line represents 
disulphide linkages and the red circular lines show the circular folding. 
1.5. SOLID PHASE PEPTIDE SYNTHESIS (SPPS) 
 As discussed in the previous section about the synthesis of proteins or 
peptides, here in this section a detailed description of solid phase peptide 
synthesis is provided. This method was introduced by Robert Bruce 
Merrifield in 1959 and in his work published in the Journal of the American 




Chemical Society [87] he reported that during "solid phase peptide synthesis" 
“Polypeptides are joined with one and other by amide bond or peptide bond”. 
These bonds form between amine groups of one amino acid (N-terminal) to 
carboxylic acid (C-terminal) of a second amino acid (Figure 9).  
 
 
Figure 9: Representation of peptide bond formation between C-terminal of 
first amino acid and the N-terminal of the second amino acid. 
Peptide chains have two terminals; the N-terminal and C-terminal). The C-
terminal is attached to polymer beads by a linking agent. Commonly used 
linking agents are di- and tri-substituted benzenes. The amino acids also have 
their amino group protected for the prevention of acid reaction with each 
other. The protective molecule is 9-fluorenylmethoxycarbonyl (Fmoc).The 




Fmoc protected amino acids also give high purity and yield as well. The 
conventional solid phase peptide synthesis (SPPS) cycle is illustrated in 
Figure 10.  
 
 
Figure 10: illustration of the Solid-phase peptide synthesis (SPPS) cycle. 
 
1.6. RESEARCH AIMS & OBJECTIVES 
 
The main aim of this project is to develop, identify, and characterise 
antimicrobial peptide sequences inspired by the antimicrobial structural 
motifs of human defensins. The peptide sequences that were synthesized by 
the SPPS method are shown in Table 8. The purity of peptides is very 
important to create novelty in the peptide sequences. This purity will give 
good antimicrobial properties.  




















PACIAGERRYG 11 1192.37 g/mole Basic Defensins 
Human 
Neutrophil 
peptide 1 & 2 
DLAMP-
2 








GTCIYQRLNAF 11 1285.49 g/mole Basic Defensins 
Human 
Neutrophil 
peptide 2 & 3 
DLAMP-
5 




CISEKTTDGHC 11 1193.32 g/mole Neutral Nad1 From 
Nicotiana Alata 
(plant protein) 
DLAPM (Defensin-like antimicrobial peptides). 









For the synthesis reaction Aldrich® System 45™ vessels with cap and fritted 
disc were purchased from Sigma-Aldrich, UK. All amino acids were N-
terminal Fluorenyl-methyloxy-carbonyl (Fmoc) protected with purity of 
>98%. Amino acid preloaded Wang resin beads (loading 0.7 - 5.3 mmol) and 
O-benzotriazole-N, N, N’, N’-tetramethyl-uroniumhexafluoro- phosphate 
(HBTU) used in Solid Peptide Phase Synthesis (SPPS) were also purchased 
from Sigma-Aldrich, UK. The amino acids and resin beads used are listed 
below:  Fmoc-Ala-OH, Fmoc-Ala-Wang resin (loading 0.33 mmol/g), Fmoc-
Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-L-Asparagine(DOD) , Fmoc-
Cys(Trt)-OH, Fmoc-Cys(Trt)-Wang resin (loading 0.7 mmol/g), Fmoc-
Glu(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Gly-Wang 
(loading 0.36 mmol/g) , Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, 
Fmoc-Phe-Wang resin (loading 0.07 mmol/g), Fmoc-Ser-OH, Fmoc-
Thr(tBu)-OH, Fmoc-Trp-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-
Lys(Boc)-OH and Fmoc-Pro-OH. N,N-Dimethylformamide (DMF), 
Dichloromethane (DCM), N,N-diisopropylethylamine (DIPEA) and 
piperidine were used as solvent and were all purchased from AGTC 
Bioproducts.  Ninhydrin for Kaiser Test was purchased from Sigma-Aldrich, 




UK. DL-Dithiothreitol (DTT) was used for inhibiting formation of Disulfide 
bonds and was purchased from Sigma-Aldrich, UK. Trifluoroacetic acid 
(TFA) and triisopropylsilane (TIPS) of HPLC grade and purity of >99% were 
purchased from Sigma-Aldrich, UK. MILLEX®HA filter paper and 
Acetonitrile [high-performance liquid chromatography (HPLC) grade] were 
also supplied by Sigma-Aldrich, UK. 
For the antimicrobial testing, Wheaton narrow mouth bottles with caps, 
Nunc® inoculating loops, Petri dishes (Polystyrene) supplied by Sigma 
Aldrich, UK were used.  For the cultivation of bacteria, Oxoid Ltd., 
Basingstoke, UK supplied the tryptic soy broth (TSB) containing 0.25% 
glucose.  
In this project, the sensitivity of the peptide bond is very important, so the 
protocol is modified as resin deprotection, activation of first amino acid, 
coupling, then double coupling of same amino acid and this step continues till 
last amino acid of the sequence.   
2.2 Solid-Phase Peptide Synthesis 
In this research project, the fluorenyl-methyloxy-carbonyl (Fmoc) protecting 
group was used. For the deprotection of N-Fmoc a short treatment of 20% 
piperidine in DMF for 30 min with shaking at 300 rpm in the tightly closed 
reaction vessel was used. The liquid was drained and the resin beads were 
washed 3 times with DMF (2mL), 3 times with DCM (2mL) and again 3 




times with DMF (2mL) and for every wash, the solution was discarded by 
vacuum filtration. Coupling of the second amino acid was done by Fmoc-
AA2 and HBTU dissolved in DMF (1.25 mL) followed by addition of DIPEA 
(0.0016 mL).The solution was mixed and added to the washed resin beads. 
This reaction usually takes 2 hours at 250 rpm to complete except for cysteine 
and arginine. Then it was filtered off by vacuum filtration and the resin beads 
were washed again. Each washed solution was discarded by vacuum 
filtration. After this, the coupling progress was monitored by the Kaiser Test 
or Ninhydrin test. This test was performed by adding 10 resin beads to the 
solution of ninhydrin in water (5/10, w: v, 1 mL) allowing them to boil for 3 
minutes. If the test was positive [blue/purple resin beads], coupling was 
incomplete. In this case, the coupling solution was discarded and new 
coupling solution was added with the use of the same amino acid. Negative 
test was indicated by pale yellow/brown colour. The complete reaction was 
followed by deprotection, wash and coupling with the next Fmoc-AA in the 
sequence. 
This cycle continued until all of the amino acids were coupled on the resin 
beads. The final deprotection of the Fmoc group was performed and again 
resin beads were washed 3 times with DMF (2mL) followed by 3 times with 
DCM (2 mL) and then 3 times with DMF (2 mL) followed by another 2 times 




with DCM (2mL) and dried finally in vacuum. The dried peptides were then 
transferred to a bottle and left open in desiccator for 24 hours.   
2.2.1. Deprotection of Fmoc Group from the N-Terminal of Amino Acid 
Resin beads were swollen by 2mL DMF for 30 minutes using an orbital 
shaker (300 rpm). Then, piperidine was used for the cleavage of the Fmoc 
protection group and the mechanism is illustrated in Figure- 12. A mixture of 
piperidine in DMF (2mL, 1:5 v: v) was added in the synthesis flask and was 
tightly closed. The flask was fit in an orbital shaker for the reaction. The 
process continued for 30 minutes with a frequency of 250 rpm. Then the 
reaction solution was removed by vacuum filtration and reaction vessel walls 
as well as the resin beads were washed three times with DMF (2mL), three 
times with DCM (2mL) and finally again three time with DMF (2mL) for 
ensuring that no piperidine residue was left in the reaction vessels. 
 
Figure 11: Representation of the Fmoc group deprotection from an amino acid. 




2.2.2. Cleavage of peptide from the resin 
The most crucial step of solid phase peptide synthesis (SPPS) is the cleavage 
of peptides from the resin. Serious care should be taken here to complete the 
reaction. Few amino acids have problems with trifluoroacetic acid (TFA) 
cleavage cocktail mentioned in Table 1. In this stipulation, protected side-
chain groups produce stabilized carbo-cations, which react with electron 
charged side chains of amino acids e.g. cysteine, methionine, tyrosine, 
threonine, serine and tryptophan and release unwanted by-products. 
Scavengers added in the cleavage cocktail to trap these carbocations. In this 
project, the cleavage cocktail consisted of 88% trifluoroacetic acid (TFA) , 
5% phenol crystals , 5% triisopropylsilane (TIPS) and 2% deionised water 
(88/5/5/2). The sequence of added chemicals should be like this: crystals of 
phenol, H2O, TIPS and TFA. After preparing the cleavage cocktail, the resin 
was added in the flask. 5mL of the cleavage cocktail for 0.5 g of resin was 
enough to saturate and swell the resin. The reaction time varied according to 
the presence of amino acids e.g. one arginine may take 4 hours, two arginine 
can take 8 hours and one cysteine can take two hours etc. The mixture was 
left for 2-8 hours stirred with the help of a magnetic stirrer. On completion of 
reaction, the cleavage mixture and the resin beads were filtered and then 
added drop by drop in to ice cold diethyl ether. Figure-13 shows the cleavage 
reaction. 





Figure 12: Illustration of the cleavage mechanism. 
 
2.2.3. Precipitation of Peptides 
The peptide solution was filtered in a clean round flask with the help of a 
filter paper. The peptide solution was added drop wise in ice cold diethyl 
ether for precipitation and the precipitate was left in -20˚C in a freezer 
overnight. Then the precipitate was transferred in an Eppendorf tube and 
centrifuged at 13,500 rpm for 4 minutes. Finally, the supernatant was 
carefully discarded in a waste bottle and the Eppendorf with the peptides 
were dried in vacuum for 2 hours and were then transferred in a freezer at -








2.3. Characterisation of Antimicrobial Peptides  
2.3.1 High Pressure Liquid Chromatography (HPLC) 
For the analysis and purification of all six peptide sequences a Dionex 
Summit High Pressure Liquid Chromatography (HPLC) system was used. 
The use of this technique for the evaluation of proteins and proteomics is very 
useful since ages. In this machine the synthetic molecule is separated on the 
basis of its hydrophobicity by using different columns (C4, C18) and a 
stationary phase (sorbent). The component of the analytical solvent passes 
through the column at different velocities which are recorded according to the 
chemical nature of each component (both stationary phase and mobile phase). 
The time at which a particular analyte elutes from the column is called 
retention time and this will characterise the features of the analyte. In this 
case, the analytical Dionex Summit equipment was used to study the purity of 
the peptides. A Dionex Summit Preparative HPLC was used also for the 
crude peptide purification.  
For the analytical HPLC, precipitated peptides were dissolved in 1ml 
Deionized water and 0.0018g Dithiothreitol (DTT). Use of DTT in all 
sequences helped to prevent disulphide bonding between cysteines. Ready 
peptide solution was injected into the column and run for 60 minutes; during 
this linear solvent gradient were 100% inorganic solvent and 0% organic 
solvent. The amount of organic solvent was increased for the elution of 




hydrophobic molecules from the column to 40% water and 60% acetonitrile. 
Finally the calculation of the initial purity was based on merging the peak 
areas. 
After collecting suitable peaks a similar procedure was performed using the 
preparative HPLC.  The peptides were filtered by MILLEX®HA filter paper 
and then were put through reverse phase-high pressure liquid chromatography 
(RP-HPLC). Different peaks represent different components. In order to 
purify the peptides, a particular component flows out of the column and is 
collected. The collected peptides were identified by mass spectrometry. 
2.3.2. Mass spectrometry 
Peptide sequences were analysed by chemical ionization-mass spectrometry 
in the School of Chemistry, University of Birmingham. This is an analytical 
technique that characterises molecules by means of measuring the masses of 
their ions. When liquid, gas or solid ionized when bombarded by electrons, 
charged fragments form [120]. The sequence of fragmentation is; ionization, 
acceleration, deflection and detection [121]. In the mass-spectra the X-axis 
represents the detected ion molecular weight divided by the charge of the ion 
(m/z) and the Y-axis represents the relative intensity.  
2.3.3. Anti-Microbial Study 
Minimum inhibitory concentration and minimum bactericidal concentration 
were measured by using methods delineated previously by Wiegand et al.  




Staphylococcus epidermidis (ATCC) and Pseudomonas aeruginosa (ATCC) 
stains were provided by Dr Izabela Radecka of the School of Biology, 
Chemistry and Forensic Sciences at the University of Wolverhampton.  
2.3.3.1. Minimum Inhibitory Concentration (MIC) 
 
500µL of tryptic soya broth (TSB) were added in all 9 sterilized bottles (see 
Figure 14). Three bottles were used for control group; one with only TSB, 
second bottle contained TSB with peptide, and third contained TSB with 
microorganism. The other five bottles contained different peptides 
concentration (35mg/mL, 17.5 mg/mL, 8.75 mg/mL, 4.375 mg/mL, 2.187 
mg/mL and 1.09 mg/mL). The bacterial culture was diluted in TSB 1:100 
[10-8 CFU per mL] and 10µL of bacterial culture were added in all bottles 
except the bottles that contained TSB and TSB with peptides. After adding 
bacterial culture the bottles were incubated for 24 hours at 37˚C. The 
sample’s turgidity was recorded as low turgidity (+), medium turgidity (++) 
and high turgidity (+++). After taking turgidity records, the bottles were 
incubated again for additional 48 hours and additional readings were taken.  





Figure 13: Dilution test. 
 
2.3.3.2. Minimum Bactericidal Concentration (MBC)  
For minimum bactericidal concentration, preparation of bacteria free agar 
plates to culture all samples for confirmation of bacterial growth was 
performed. Agar plates were divided into four parts (three parts for peptides 
and one for penicillin as a control group) for spreading bacteria culture. A 
sterilised Inocular was used to spread bacterial culture and all samples were 
incubated in 37˚C for 24 hours (Figure 15). P. aeruginosa growth was 
different and had a green colour, whereas S.epidermidis was opaque. 





Figure 14: Agar plate test for measuring the minimum bactericidal concentration (MBC).
 
 





Chapter 3: RESULTS AND DISCUSSION  
 
3.1. Fluorenyl-methyloxy-carbonyl (Fmoc) Solid Phase Peptide Synthesis 
The human defensins-like peptide structures were synthesized by fluorenyl-
methyloxy-carbonyl (Fmoc) solid phase peptide synthesis (SPPS) and for 
better peptide linkage between amino acids, double coupling of peptides was 
performed without labelling to avoid the influence of the dye on the 
antibacterial properties [122]. Although the fluorenyl-methyloxy-carbonyl 
(Fmoc) solid phase peptide synthesis method is commonly performed to 
synthesise peptides, many complex reactions are still performed using the 
original tert-butyl-oxy-carbony (Boc) chemistry. The original Boc method is 
performed when un-natural amino acids or other derivatives that are base 
sensitive are incorporated into the sequence. In this project, peptides have 
different sequences, number of amino acids, charges and molar masses (Table 
9). In order to confirm the desired amino acids sequence and purity of 
peptides, high pressure liquid chromatography (HPLC) and mass 
spectrometry were used as previously described [122, 123]. 
 
 




Table 9: Amino acid sequences, charges, and theoretical molar mass of 
synthesised human defensins-like AMPs. 
Codes Peptide 
Sequence 




DLAMP-1 PACIAGERRYG 11 1 1192.37 g/mole 
DLAMP-2 CATRESLSGVC 11 0 1125.29 g/mole 
DLAMP-3 CRVRGGRCA 9 3 977.18 g/mole 
DLAMP-4 GTCIYQRLNAF 11 1 1285.49 g/mole 
DLAMP-5 GTCGLPGTKCC 11 1 1039.27 g/mole 
DLAMP-6 CISEKTTDGHC 11 0 1193.32 g/mole 
3.2. High Pressure Liquid Chromatography 
 
Analytical reverse-phase high pressure liquid chromatography (RP-HPLC) 
was performed on a Shimadzu operating system located in the School of 
Chemistry, University of Birmingham. The partial purification of synthetic 
defensin-like antimicrobial peptide-1 (DLAMP-1) using reverse phase high 
performance liquid chromatography (RP-HPLC) is shown in Figure 16. The 
major peak of around 500 mAU was obtained at 21.76 minutes. Some other 
smaller peaks are also eluted but the absorbance of all these peaks was below 
100 mAU. The LC program was binary with general water methanol mobile 
phase system. The gradient was set as 0 - 100% B in 40 minutes, then 100% 
B  for 9 minutes and then back to initial condition of 0% B in 50 minutes. The 
absorbance was read at 210 nm. The flow rate was 1ml/minutes. 





Figure 15: Reverse phase-High pressure liquid chromatography (RP-HPLC) of Defensins -
like antimicrobial peptide─1 (DLAMP-1). 
The purification of synthetic defensin-like antimicrobial peptide - 1 
(DLAMP-1) collected from the first HPLC run was again applied on reverse 
phase high performance liquid chromatography (RP-HPLC) and is shown in 
Figure 17. The major peak at around 475 mAU was obtained at 21.35 
minutes. The LC program was binary with general water methanol mobile 
phase system. The gradient was set as 100% B at 40 minutes, then 100% B 
for 9 minutes and then reach to 0% B in 50 minutes. The absorbance was read 
at 210 nm. The flow rate was 1ml/minutes. 





Figure 16: High pressure liquid chromatography (HPLC) of purified collected peaks of 
Defensins -like antimicrobial peptide─1 (DLAMP-1). 
The partial purification of synthetic defensin-like antimicrobial peptide-2 
(DLAMP-2) on reverse phase high performance liquid chromatography (RP-
HPLC) has been shown in Figure 18. The major peak at around 225 mAU 
was obtained at 19.30 minutes together with some other minor peaks but the 
mAU of all of those were below 120. The liquid chromatography (LC) 
program was binary with general water methanol mobile phase system. The 
gradient is set as 100% B in 40 minutes then 100% B for 9 minutes and then 
reach to 0% B at 50 min. The absorbance was read at 210nm at a flow rate of 
1ml/minutes. 





Figure 17: Reverse phase-High pressure liquid chromatography (RP-HPLC) of Defensins -
like antimicrobial peptide – 2 (DLAMP-2). 
For final purification; the collected defensin-like antimicrobial peptide - 2 
(DLAMP-2) on (RP-HPLC) has been shown in Figure 19. The major peak at 
around 250 mAU was obtained at 19.05 minutes. The liquid chromatography 
(LC) program was binary with general water methanol mobile phase system. 
The gradient is set as 100% B in 40 minutes then 100% B for 9 min and then 
reach to 0% B at 50 minutes. The absorbance was read at 210nm at flow rate 
of 1ml/minutes. 
 





Figure 18: High pressure liquid chromatography (HPLC) of purified collected peaks of 
Defensins -like antimicrobial peptide─2 (DLAMP-2). 
The partial purification of synthetic Defensin-like antimicrobial peptide-3 
(DLAMP-3) on (RP-HPLC) has been shown in Figure 20. The major peak at 
around 155 mAU was obtained at 17.32 minutes. Some other smaller peaks at 
lower than 30 mAU were also obtained. . The LC program was binary with 
general water methanol mobile phase system. The gradient is set as 100% B 
in 40 minutes then 100% B for 9 minutes and then reach to 0% B at 50 
minutes. The absorbance was read at 210 nm at a flow rate of 1ml/minutes. 
 





Figure 19: Reverse-phase high pressure liquid chromatography (HPLC) of Defensins -like 
antimicrobial peptide─3 (DLAMP-3). 
The purification of synthetic Defensin-like antimicrobial peptide - 3 
(DLAMP-3) on (RP-HPLC) has been shown in figure-21. The major peak at 
around 600 mAU was obtained at 17.37 minutes. The LC program was binary 
with general water methanol mobile phase system. The gradient was set as 
100% B in 40 minutes then 100% B for 9 minutes and then reach to 0% B at 
50 minutes. The absorbance was read at 210nm at a flow rate of 1ml/minutes. 
 





Figure 20: High pressure liquid chromatography (HPLC) of collected peaks of Defensins -
like antimicrobial peptide─3 (DLAMP-3). 
 
The RP-HPLC of synthetic Defensin-like antimicrobial peptide - 4 (DLAMP-
4) is shown in Figure 22. The chromatogram showed two early eluting peaks 
at 3.3 and 5.9 minutes and some broad peaks with shoulders. Broad peaks 
were expected due to aggregation of peptides or degradation of peptides into 
smaller fragments. The gradient program and flow rate used was same as 
described in Figure 16.  
 
 






Figure 21: Reverse phase-High pressure liquid chromatography (RP-HPLC) of Defensins -
like antimicrobial peptide – 4 (DLAMP-4). 
The RP-HPLC of synthetic Defensin-like antimicrobial peptide - 5 (DLAMP-
5) is shown in Figure 23. The chromatogram showed some high intensity base 
line peaks at 5.7 and 8.02 minutes and some broad peaks with shoulders. 
Broad peaks were expected due to degradation of product or aggregation of 
peptide. The gradient program and flow rate used was the same as described 
in Figure 16. 





Figure 22: Reverse phase-High pressure liquid chromatography (RP-HPLC) of Defensins -
like antimicrobial peptide – 5 (DLAMP-5). 
The RP-HPLC of synthetic Defensin-like antimicrobial peptide - 6 (DLAMP-
6) is shown in Figure 24. The chromatogram showed some high intensity base 
line peaks at 3.14, 5.79 and 7.99 minutes and some broad peaks with 
shoulders. Broad peaks were expected due to aggregation of peptides. The 
gradient program and flow rate used was the same as described in Figure 16.  





Figure 23: Reverse phase-High pressure liquid chromatography (RP-HPLC) of Defensins -

















3.3. Mass Spectrometry  
 
Time of flight mass spectrometer with electron spray ionization (TOF MS 
ESI) source in School of Chemistry, University of Birmingham were used to 
find the experimental mass of synthetic peptide DLAMP-1 in positive mode. 
The spectra contain mass to charge ratio (m/z) on x-axis and percentage on y-
axis. In this two major ion peaks are obtained. The first peak having 400 mass 
with 100% intensity. The second peak showed the mass of 600 with 
approximately 30% intensity and 342.5 and 489.2 are mass of fragmented 
peptides. After calculations it was found that the peaks possess +3 (400.6mz) 
and +2 (600.3mz) charge respectively. The sum of experimental mass is 
about 1200 Da which is absolutely near to theoretical mass i.e., 1192 Da.  
This may be indicative of difference in sequence of peptide that might 
occurred during synthesis. 





Figure 24: Mass-spectrometry of purified peptide (DLAMP-1) after freeze dried. 
Time of flight mass spectrometer with electron spray ionization (TOF MS 
ESI) source was used to find the experimental mass of synthetic peptide 
DLAMP-2 in positive mode. The spectra contain mass to charge ratio (m/z) 
on x-axis and percentage on y-axis. In this case only one major ion peak was 
obtained with 100% intensity having mass of 716.9 Da. The experimental 
mass was not in accordance with theoretical mass which was 1125.29 Da. 
The peak obtained was found to be +2 charged. This may be indicative of 
difference in sequence of peptide that might occurred during synthesis. 





Figure 25: Mass-spectrometry of purified peptide (DLAMP-2) after freeze dried. 
Time of flight mass spectrometer with electron spray ionization (TOF MS 
ESI) source was used to find the experimental mass of synthetic peptide 
DLAMP-3 in positive mode. The spectra contain mass to charge ratio (m/z) 
on x-axis and percentage on y-axis. In this case only one major ion peak is 
obtained with 100% intensity having mass of 707.9 Da. The experimental 
mass is not in accordance with theoretical mass which is 977.18 Da. The peak 
obtained was found to be +2 charged.  





Figure 26: Mass-spectrometry of purified peptide (DLAMP-3) after freeze dried. 
3.4. Antimicrobial Study (MIC/MBC)  
 
To sum up all observations, we concluded that all three peptides have 
different antibacterial activity due to different amino acids, charges and 
polarity. In this study, high arginine peptide sequence showed better results 
than others. In clinical microbiology; use of antibiotics to inhibit or kill 
bacteria at different concentration and for this combination minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC) were used. In this research dilution test (serial solution test) was used 
[124]. For minimum inhibitory concentration (MIC) of synthetic peptides 




reading were measured on the basis of turbidity of solution e.g.  Low turbidity 
(+), medium turbidity (++), high turbidity (+++) and no turbidity (Clear). At 
low DLAPM-1, 2 and 3 concentration of less than equal to 2.187 mg/mL, the 
viability of S. epidermidis and P. aeruginosa were more than 98%. Even 
when concentration was increased to 8.75 mg/mL of DLAMP (1, 2 and 3), 
the viability of S. epidermidis and P. aeruginosa were still 91.95% and 
95.95% respectively and all assays were performed twice. At concentration 
17.5mg/mL of DLAMP-3 and DLAMP-2 showed medium turbidity against 
S.epidermidis not for P. aeruginosa medium. Similarly at concentration of 
17.5 mg/mL of DLAMP-1 demonstrated no or minor bactericidal effect 
against S. epidermidis and P. aeruginosa.  In control groups, we observed no 
bacterial growth reflecting the non-contaminated environment. All work was 
conducted in a fume cupboard to control contamination. Tables 10 and 11 
show all concentration of peptides and microorganisms. DLAMP-3 
maintained their effect against S.epidermidis and P. aeruginosa medium from 
35 mg/mL to 4.375 mg/mL of concentrations. The reason was their short 
amino acid architecture (9 amino acids), net charge and high arginine (R) 
content as compared to other synthetic peptides. As previously described by 
Zou et al. about the effect of introducing arginine (R) in α-defensins in 
contrast to lysine (K) [125]. Another study reported that replacing arginine 
(R) affects the antimicrobial activity as well as the salt sensitivity in analogs 
of Human β- defensins [126]. For antimicrobial peptide, higher net charge 




and arginine residues are required is reported in Antimicrobial Peptide 
Database (http://aps.unmc.edu/AP/main.php).  
Table 10: Peptides concentration against S. epidermidis. 
Groups DLAMP- 1 DLAMP-2 DLAMP-3 
TSB Clear Clear Clear 
TSB + Peptides Clear Clear Clear 
TSB + Peptides +D2O +++ +++ +++ 
TSB + 35mg/mL + + + 
TSB + 17.5mg/mL +++ + + 
TSB + 8.75mg/mL +++ ++ ++ 
TSB + 4.375mg/mL +++ +++ ++ 
TSB + 2.187mg/mL +++ +++ +++ 
TSB + 1.09mg/mL +++ +++ +++ 
Tryptic soya broth (TSB), + [low turbidity] = visible growth and high cell death of microorganisms, 
++ [Medium turbidity] = visible growth, low cell death and slightly opaque solution, +++ [High 
turbidity] = visible growth, no cell death and totally opaque solution, Clear [no turbidity].  
 
Table 11: Peptides concentration against P. aeruginosa. 
Groups DLAMP- 1 DLAMP- 2 DLAMP- 3 
TSB Clear Clear Clear 
TSB + Peptides Clear Clear Clear 
TSB + Peptides +D2O +++ +++ +++ 
TSB + 35mg/mL ++ +++ + 
TSB + 17.5mg/mL +++ +++ ++ 
TSB + 8.75mg/mL +++ +++ ++ 
TSB + 4.375mg/mL +++ +++ ++ 
TSB + 2.187mg/mL +++ +++ +++ 
TSB + 1.09mg/mL +++ +++ +++ 
Tryptic soya broth (TSB), + [low turbidity] = visible growth and high cell death of microorganisms, 
++ [Medium turbidity] = visible growth, low cell death and slightly opaque solution, +++ [High 
turbidity] = visible growth, no cell death and totally opaque solution and Clear [no turbidity].  
 
The minimum bactericidal concentration (MBC) dose of antibiotics to kill 
bacterial cells was identified. In this study the control group drug was 




ampicillin for both selected bacteria and a good killing zone was observed as 
compared to DLAMP-3 against S. epidermis and P. aeruginosa (Figure 28). 
DLAMP-1 also shows few micrometre bacterial killing zones against 
S.epidermidis. DLAPM-2 have no or less zone of killing S. epidermis and P. 
aeruginosa.  
 
Figure 27: Represents all peptides with Ampicillin against S. epidermidis and 
P.aeroginosa. In peptide 3 clearly visible zone of inhibition and in peptide 1 few micron 
zones are visible. 
Our defensins-like antimicrobial peptide (DLAPM) -1, 2, and 3 have arginine 
and cysteine in their design so they gave antibacterial activity during 
MIC/MBC. The coupling in remaining sequences (DLAMP-4, 5, and 6) was 
most likely due to aggregation or formation of unwanted products due to long 
sequences or due to poor motifs from Human defensins is still questionable. 
Host defense antimicrobial peptides (AMPs) are important component of 
innate immunity of both vertebrates and invertebrates [127]. One group of 




researchers reported the total synthesis of Human α- defensins 4, 5, and 6 and 
they mimicked Human neutrophil peptides-4, Human defensins-5 and 6, in 
which they used oxidative folding with disulfide bridges protocol and 
received high yield purity (10% to 16%) and culture them in colony forming 
methods LD50, LD90 of E. coli ATCC 252922 and S. aureus ATCC 29213  
[128].  Hoover Et al. and his co-workers worked on linear peptides with 
native disulfide bridge and without bridge to evaluate the antibacterial and 
antifungal activity of human defensins peptide-3, with the protocol of tert-
butyloxycarbonyl (Boc) solid-phase peptide synthesis although experiment is 
different from this project but the design and concept is same to create human 
defensins nature based cores [129]. Developing short defensins with disulfide 
bridge help in stabilizing role in inhibiting of microorganisms [79]. Very 
recently Wang et al. evaluated antimicrobial activity of human β-defensin-1 
(hBD-1), human β-defensin-2 (hBD-2) and β-defensin-3 (hBD-3) against 
three common probiotic strains of lactic acid bacterium (Bifidobacterium 
longum JDM301, Bifidobacterium lactis HN019 and Lactobacillus 
rhamnosus GG (LGG), but viability of lactic acid bacteria were very high at 
concentration of 10µg hBD/mL. Then they introduced carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) to inhibit efflux pumps as previously 
described, showed potent activity against B. longum JDM301, and B. lactis 
HN019 not for Lactobacillus rhamnosus GG (LGG) [130].  




According to the antimicrobial data base (http://aps.unmc.edu/AP/main.php ) 
reportedly cationic peptides are positively charged due to the presence of lysine 
(K) and arginine (R) residues also histidine (H) in their sequences. Human 
defensins are with high net charge (positive) and have high antibacterial, 
antifungal, antiviral or anticancer capabilities. The attraction between lipid 
membranes and peptides, obviously with high positive charged antimicrobial 
peptides attracted with negative charged membranes [131]. The reason behind 
this is too high positive charge of peptides will decrease the membrane activity 
and create strong electrostatic interactions with lipid head group region. Another 
possibilities are repulsions between positives charges of side chains or may be 
due to more negative charges on membrane lips attracts positive charged 
peptides [46]. In Table 12, a description of human β- defensins peptides with 
their name, sequence, net-charge and references is presented. 
Table 12: Description of Human Beta (β) - Defensins sequences and net charges with 

















HBD-28 ARLKKC-FNKVTGYCRK-KCKVGERYEIGC-LSGKLCCAN +8 [136] 




CHAPTER 4: CONCLUSIONS AND FUTURE WORK 
4.1. Conclusions 
 
We concluded novel human defensins antimicrobial peptides analogs or 
motifs for making antibiotics and antimicrobial biomaterial surfaces. To this 
aim, we mimicked natural Human defensins namely defensins human 
Neutrophil peptide 1-2, human α-defensins-5, human β- defensin-3, defensins 
human neutrophil peptide 2-3, human β-defensin 2 and Nad1 From Nicotiana 
Alata (plant protein) by solid-phase peptide synthesis (SPPS). In this 
experiment design is linear and short peptides to evaluate the purity 
percentage, minimum inhibitory concentration and minimum bactericidal 
concentration of all six sequences but unfortunately we achieved only three 
peptides in pure percentage around 98% and amount for antibacterial testing. 
DLAMP-1 (PACIAGERRYG), DLAMP-2 (CATRESLSGVC) and DLAMP-
3 (CRVRGGRCA) showed purity of 98% and they give inhibitory effect 
against S. epidermidis and P. aeruginosa. DLAMP-3 (CRVRGGRCA) is 
more active compared to DLAMP-1 (PACIAGERRYG) and DLAPM-2 
(CATRESLSGVC) because of its net charge, presence of arginine (R) and 
cysteine in its design. We used different concentration of 35 mg/mL, 17.5 
mg/mL, 8.75 mg/mL, 4.375 mg/mL, 2.187 mg/mL and 1.09 mg/mL with 
tryptic soy broth (TSB) of all samples to measure the dose concentration at 
which inhibition or killing of microorganisms occurs. DLAMP-3 




(CRVRGGRCA) showed high inhibitory effect on S. epidermidis at 4.37 
mg/mL. For P. aeruginosa only DLAMP-3 (CRVRGGRCA) showed an 
effect at 35 mg/mL and other peptides had no or little effect. The minimum 
bactericidal concentration (MBC) test showed that an inhibitory zone in 
Ampicillin (control group), DLAMP-3 and DLAMP-1 was observed.    
4.2. Future Work 
With the successful synthesis of Human defensins peptides and plant 
defensins, work can begin on determining molecular principles and structural 
properties against infection creating organisms. Once it will fully understand 
will be used as synthetic drug for coating in medical and dental implants as 
well as incorporate in bone cement materials to create antibacterial capability. 
A list of work reported in last few years on creating or developing 
antimicrobial medical and dental implants is shown in Table 13. 
Table 13: Antimicrobial peptide based medical and dental implants. 
Years Title of Reported 
research 
Conclusion References 
2010 Controlling the release of 
peptide antimicrobial 
agents from surfaces 
Successful incorporation and 
release of an AMPs, ponericin 
G1, from hydrolytically 
degradable LbL assembled thin 
films and successful Layer-by-
layer assembling. 
[137] 
2011 The biocompatibility and 
biofilm resistance of 
implant coatings based on 
hydrophilic polymer 
brushes conjugated with 
antimicrobial peptides 
Successful creation of a biofilm 
resistant, non-toxic hydrophilic 
polymer coatings having broad 
spectrum antimicrobial 
peptides on surfaces. 
[68] 




2012 Drug release and bone 
growth studies of 
antimicrobial peptide-
loaded calcium phosphate 
coating on titanium 
Capability of an antimicrobial 
coating while maintaining 
osseointegration, AMP-CaP 
coating can effectively kill S. 
aureus, and P. aeruginosa 
bacteria and in vivo test no 
involvement of peptides 
coating in bone growth. 
[77] 
2013 Bio-inspired stable 
antimicrobial peptide 
coatings for dental 
applications 
Functionalized titanium with 
GL13K, a novel bio-inspired 
coating, antimicrobial against 
P. gingivalis and a putative 
pathogen of peri-implantitis 
[138] 
2014 Covalent immobilization of 
hLf1-11 peptide on a 
titanium surface 
reduces bacterial adhesion 
and biofilm formation 
Successfully immobilize the 
antimicrobial peptide, the 
covalent attachment of the 
hLf1-11 peptide to titanium 




zirconia and new 
zirconia/titanium 
biocermets for dental 
applications 
Successfully developed 
functional bio-coatings on 




Also investigate the reason for not purifying peak in DLAMP-4 
(GTCIYQRLNAF), DLAMP-5 (GTCGLPGTKCC) and DLAMP-6 
(CISEKTTDGHC) after synthesis same as other peptides sequences. May be 
design of sequence affect, number of amino acids or charge of the sequence 
on the purification. There is need for larger amounts of peptides with 
antimicrobial properties. The more amount will open the gate for culture them 
with other microorganisms. It has been already reported that Human 
defensins antimicrobial peptides have capability to inhibit bacteria (Gram -ve 
and Gram +ve), fungal colonies and viral activities [78].  They can be 




cooperated in denture base materials as an antifungal substitute. Hip implants 
are failed most commonly by microbial infection, need for modification their 
surface with antibacterial agents and these synthesized peptides are good 
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